





































0Vaccine 34 (2016) 2996–3000
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
tatus  of  vaccine  research  and  development  of  vaccines
or  Chagas  disease
oreen  M.  Beaumiera,b,c, Portia  M.  Gillespiea,b,c, Ulrich  Strycha,b,c, Tara  Haywardd,
eter  J.  Hoteza,b,c,d,e,f, Maria  Elena  Bottazzia,b,c,d,e,f,∗National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA
Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA
Sabin Vaccine Institute, Washington, DC, USA
Department of Biology, Baylor University, Waco, TX, USA
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. About the disease and pathogen
Chagas disease (American trypanosomiasis caused by Try-
anosoma cruzi) is a vector-borne parasitic infection transmitted
y triatomines (kissing bugs), today considered one of the most
mportant neglected tropical diseases globally (NTDs) [1].
.1. Global disease and economic burden
An estimated 7–8 million people are infected worldwide with
lmost all of the cases occurring in the Americas, predominantly
n the poorest countries in the region [2–4]. However, revised esti-
ates taking into consideration underreporting and poor diagnosis
uggest that the number of total worldwide Chagas cases is much
loser to 9–10 million [5,6]. Further estimates are that Chagas dis-
ase is responsible for 10,600 deaths per year in addition to 97,500
ears lived with disability (YLDs) [5,7]. In total, combining years
f life lost and YLDs, Chagas disease causes approximately 0.6 mil-
ion disability adjusted life years (DALYs), a measure integrating a
isease’s morbidity and mortality [4,5,8]. According to the World
ealth Organization, currently the largest number of people living
ith Chagas disease are found in focal areas of poverty within Latin
merica’s three wealthiest countries: Argentina (1.5 million), Brazil
1.2 million), and Mexico (0.9 million), while the highest prevalence
f the disease (in terms of percentage of the population infected
ith T. cruzi) is seen in Bolivia (6.104 cases per 100 people) [7]. Cha-
as disease has also become “globalized” with thousands of cases
lso found in Southern Europe, Australia, and Japan [9]. Also, of
articular concern are the large numbers of cases in the southern
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a signiﬁcant level of autochthonous transmission [10,11].
Despite its global importance in the most affected Western
Hemispheric countries, it is estimated that only a small percent-
age of Chagas disease patients are diagnosed and receive access to
essential medicines and other healthcare [12]. Patients with Cha-
gas disease typically live in extreme poverty and represent a highly
vulnerable population. The poor who live in the Western Hemi-
sphere’s wealthiest countries, including Argentina, Brazil, Mexico,
and the United States are especially neglected, a concept consistent
with the tenets of “blue marble health” [13]. Moreover, Chagas also
has an important impact on veterinary public health, with canines
and sylvatic mammals serving as important reservoir hosts.
In addition to its global health impact, Chagas disease has been
demonstrated to be one of the largest causes of why  Latin America’s
poorest population, the “bottom 100 million”, remain impover-
ished ($7 billion annual losses to the economy) [14,15].
1.2. Natural history and clinical disease
Typically, the T. cruzi protozoan parasite enters its vertebrate
hosts with insect faeces deposited into fresh bite sites, mucosal
surfaces or other skin breaks. In its trypomastigote form the par-
asite then can invade cells such as ﬁbroblasts, macrophages, and
epithelial cells, thus largely evading the host’s immune system.
Within its mammalian host the parasite then transforms into its
intracellular amastigote form, and concomitant with the even-
tual rupture of these host cells, blood-form trypomastigotes are
released. The cycle is completed when triatomines take up trypo-
mastigotes during subsequent feedings, and the parasite develops
into the epimastigote form in the midgut, which multiplies by
binary ﬁssion, and back into trypomastigotes in the hindgut [16].Exposure to the T. cruzi parasite results in the development of
an acute infection, which is often asymptomatic and lasting for 4–8
weeks, but can also be characterized by a rather telling localized
swelling at the site of infection (Chagoma), or a special form of
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onjunctivitis (Roman˜a’s sign). Virtually all of these acutely infected
ndividuals seroconvert to T. cruzi, but approximately 60–70% of
hese individuals do not progress to clinically apparent disease
indeterminate status),  while the remaining 30–40% move on to
evelop the chronic form of the disease (determinate status),  con-
omitant with the appearance of cardiac and/or gastrointestinal
igns and symptoms. Cardiac complications in particular, occurring
n 20–30% of patients, cause the most severe morbidity and mor-
ality and are characterized by arrhythmias, aneurysms, and heart
ailure. Ventricular tachycardia and ﬁbrillation leading to sudden
eath are connected to two-thirds of the mortalities from Chagas
isease, followed closely by heart failure and thromboembolism
17]. Pathological ﬁndings in chronic Chagasic gastrointestinal dis-
ase include dilatation and muscular hypertrophy of the colon or
he oesophagus, as well as injury to the parasympathetic nervous
ystem [18].
While most of Chagas disease occurring in the Americas is trans-
itted by triatomines, there is now also evidence for increasing
aternal-to-child transmission of the disease, resulting in congen-
tal Chagas disease. Hundreds of thousands of pregnant women
n the Americas now live with Chagas disease, while maternal-to-
hild transmission of T. cruzi leading to congenital Chagas disease
as resulted in 8668 documented neonates infected in Latin Amer-
ca (in 2010), with Mexico having the largest number of cases of
ongenital Chagas disease [7], though these estimates do not likely
epresent the true number of cases due to poor detection of the
isease [19,20].
.3. Current approaches to treatment
Current treatment is dependent on two drugs, benznidazole or
ifurtimox, both of which are highly effective, provided therapy
s initiated at the onset of infection and during the acute phase
f the disease. However, very few patients are diagnosed in the
cute stages because these stages are often silent, or because the
atients do not have access to proper diagnosis and treatment. The
fﬁcacy of both drugs for many patients with chronic Chagas dis-
ase diminishes the longer a person has been infected. In fact, a
ecent randomized trial of patients showing evidence of Chagasic
ardiomyopathy failed to show any beneﬁt for patients treated with
enznidazole versus an untreated control cohort when it came to
he progression of cardiac clinical deterioration [21]. Therefore, the
eneﬁts of medication in preventing or delaying the development
f Chagas disease has to be weighed against the long duration of
reatment (up to two months) and relatively high rates of adverse
eactions that occur in up to 40% of treated patients. Furthermore,
he drugs are contraindicated in pregnancy and for those with kid-
ey or liver failure. Additionally, speciﬁc treatment for cardiac or
igestive manifestations may  be required. Up to 20% of patients
annot tolerate full treatment courses [22,23]. Given this current
ituation, there is an urgent need for a new treatment strategy is
rucially needed for chronic Chagas disease, including a safe and
ffective vaccine.
. Overview of current efforts
.1. Biological feasibility for vaccine development
Currently there are at least two major potential Target Prod-
ct Proﬁles (TPPs) for a Chagas disease vaccine (Box 1). The ﬁrst
s a prophylactic vaccine that would prevent acute infection and
he second is a therapeutic vaccine for patients that have sero-
onverted and are at the indeterminate stage. It is widely noted
hat a therapeutic or preventative T. cruzi vaccine would be highly
eneﬁcial in controlling Chagas disease [23,24]. A preventative 34 (2016) 2996–3000 2997
vaccine if used in highly endemic areas could potentially prevent
acute infection (especially in a hyperendemic setting found in some
parts of Latin America) but is unlikely to interrupt disease transmis-
sion because of the large number of animal reservoirs and zoonotic
hosts, typically found in these endemic areas. A therapeutic vaccine
administered alone or in combination with chemotherapy would
be used to prevent or delay the onset of Chagasic cardiomyopathy in
patients who  have seroconverted to T. cruzi infection and are at the
indeterminate or early determinate stage [15]. Hence a third TPP
would include the use of a therapeutic vaccine used in conjunction
with benznidazole or other newly developed antiparasitic drugs.
Some investigators refer to this combination as “vaccine-linked
chemotherapy”.
Box 1: TPPs for Chagas disease vaccine
Preventive Chagas disease vaccine
Therapeutic Chagas disease vaccine in patients with indeter-
minate infection
Therapeutic Chagas disease vaccine linked to anti-parasitic
chemotherapy (‘vaccine linked chemotherapy’)
Cost-effectiveness studies have been conducted on both the
preventive and therapeutic vaccine TPPs [14,15,25]. While both
are considered cost-effective, the therapeutic vaccine is considered
more cost-effective and cost-saving and therefore more econom-
ically dominant [15]. There is as yet no consensus among the
community of Chagas disease researchers on the urgency for devel-
oping a prophylactic vaccine. However, there is general agreement
on the need for new therapeutic anti-trypanosomal products that
go beyond the currently available drugs, benznidazole and nifur-
timox.
Both scientiﬁc and socioeconomic challenges have hindered
the development of vaccines against Chagas disease. Chagas dis-
ease is an NTD almost exclusively affecting people in poverty and
thus there has been an absence of market incentive for pharma-
ceutical companies to undertake research and development on
a vaccine. In addition, initial safety concerns over exacerbating
pre-existing cardiac lesions through activation of an autoimmune
reaction, based on earlier assertions that there is an important
autoimmune component to Chagas disease pathogenesis. However,
most investigators currently believe that it is parasite persistence
that is associated with disease progression, and that a strong CD8+ T
cell immune response will need to be induced, encompassing either
interferon-gamma or cytotoxic activity, or both, in order to control
T. cruzi infection through vaccination [18,22,23].
Evidence from the testing of a wide range of vaccine formula-
tions over the years that range from whole parasites, to puriﬁed
or recombinant proteins, viral vectors and DNA vaccines have pro-
vided preliminary pre-clinical proof-of-concept for vaccination as
a preventive and potentially therapeutic strategy. It has further
been observed that the efﬁcacy of T. cruzi vaccines in pre-clinical
models will be greatly inﬂuenced by the vaccine formulations used
and their resulting immune response [22,23]. Along these lines,
many preclinical models have been employed in the study of Cha-
gas disease, most of which include rodents, dogs, and non-human
primates (NHP). The advantages of rodent models, most commonly
mice, are lower cost for housing and handling, and a shorter life-
span resulting in quicker results. However, it is often difﬁcult for
the murine systems to completely reﬂect the pathology seen in
human Chagas disease. Canine and NHP models often more success-
fully mimic  the human responses and pathologies observed, but,
with their longer lifespan, experimental results are often delayed.
In addition, ethical concerns that surround their use and the
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Table 1
Development status of current vaccine candidates.
Candidate Name/identiﬁer Developer Platform/antigens Preclinical References
Tc24 UADY, CINVESTAV, Sabin Vaccine Institute-PDP DNA, recombinant protein X [34,35]
TSA-1 UADY, CINVESTAV, Sabin Vaccine Institute-PDP DNA, recombinant protein X [35,36]
Live attenuated Trypanosoma
cruzi
Universidad Nacional de Salta Live attenuated parasite X [37,38]
Live T. rangeli Universidad Nacional de Córdoba Live parasite X [39,40]
ASP-2 Universidade Federal de São Paulo Adenoviral vector X [41–43]
TS Universidad Nacional del Litoral Recombinant protein X [44]
Cruzipain Consejo Nacional de Investigaciones Cientíﬁcas
y  Técnicas-Universidad de Buenos Aires
Salmonella vector X [45,46]
GP83 University of Alabama at Birmingham Adenoviral vector X [47]
TSSA CD8+ epitope Universidade de São Paulo Recombinant protein X [48,49]
Tc52 Consejo Nacional de Investigaciones Cientíﬁcas
y  Técnicas-Universidad de Buenos Aires







































dTcG1, TcG2, TcG4, TcVac2,
TcVac4
University of Texas Medical Branch 
MASP University of Texas at El Paso 
igniﬁcant increase in cost involved must be considered when plan-
ing these studies [26].
.2. General approaches to vaccine development for this disease
or low- and middle-income country markets
As alluded to above, several recent preclinical studies have
sed recombinant proteins, recombinant viral (adenovirus) vec-
ors, DNA platforms, and heterologous prime-boost vaccination
egimens and elicited protection against infection and increased
urvival in murine models (Table 1).
The success of either a preventative or therapeutic vaccine
ould depend on its ability to induce a TH1-mediated immune
esponse suggesting that the same antigens and formulations
ould be efﬁcacious for both types of vaccine. A therapeutic vaccine
hough, as a standalone therapy or used together with benznida-
ole and nifurtimox in a vaccine-linked chemotherapy approach,
s likely the currently desired (and probably most feasible) strat-
gy for vaccine development with the potential to reduce the dose
nd/or the treatment duration, therefore ultimately reducing the
oxicity of current and even emerging chemotherapeutics [15].
It is estimated that an effective vaccine could have a signiﬁcant
mpact on the prevention of cardiac complications. This would be of
aramount importance given the approximately 40,000 new cases
f Chagas disease that occur in Latin America every year. Remark-
bly, it is estimated that a vaccine would further prevent 10,000
eaths or more annually and would save up to 600,000 DALYs,
aused by cardiomyopathy and gastrointestinal disease [2,27]. In
ddition, it is expected that a vaccine could serve to reduce child
ortality and improve maternal health and pregnancy outcome
n Latin American countries and could simultaneously reduce cost
f treatment for this disease, while increasing efﬁcacy in treating
isease symptoms [25,28].
. Technical and regulatory assessment
Currently no clinical trials have begun for a Chagas disease vac-
ine. However, national regulatory agencies for endemic countries
uch as the U.S. Food & Drug Administration (FDA), Comisión
ederal para la Protección contra Riesgos Sanitarios (COFEPRIS,
exico), European Medicines Agency (EMA) and Agência Nacional
e Vigilância Sanitária (ANVISA, Brazil) could be engaged following
ubmission of an Investigational New Drug application. The criti-
al path for clinical development could likely involve a ﬁrst test of
afety of the vaccine in an NHP model prior to ﬁrst-in-human trials.
t has been noted that a signiﬁcant percentage of NHPs living out-




Hemisphere are actually infected with T. cruzi [29]. The param-
eters used to evaluate proof-of-concept may  be similar to those
employed for evaluating new small molecule therapeutics includ-
ing parasitemia [30]. In addition, efforts are underway at PAHO
and the WHO  to assess the response to anti-parasitic treatment
in the chronic phase of the disease, which we expect to be
equally beneﬁcial for the evaluation of vaccine efﬁcacy in humans
[31].
4. Status of vaccine R&D activities
A variety of different approaches to the development of Chagas
vaccines is underway as shown in Table 1. These approaches range
from immunization with attenuated parasites of non-pathogenic
Trypanosoma strains, to DNA vaccines and recombinant protein
vaccines. Additionally, the combination of various candidate anti-
gens into a multivalent strategy is also being explored. Currently,
all candidates are still in the preclinical phase of testing and not yet
in clinical trials.
Pre-clinical testing is currently underway for several therapeu-
tic vaccine candidates in mice, dogs, or non-human primates at
academic-based institutions (Table 1, [32]). Many of these can-
didates are DNA vaccines undergoing testing in mice. The Sabin
Vaccine Institute Product Development Partnership (Sabin PDP),
in collaboration with the Carlos Slim Foundation, the Universidad
Autónoma de Yucatán, the Laboratorios de Biológicos y Reactivos
de México, and the Centro de Investigación y de Estudios Avan-
zados del Instituto Politécnico Nacional, is pursuing a therapeutic
vaccine comprised of recombinant antigens expressed in yeast or
bacteria and formulated with an immunostimulant [24]. In addi-
tion, the Sabin PDP collaborates with several other academic groups
of investigators to evaluate and test their vaccine candidates.
5. Likelihood for ﬁnancing
According to G-Finder, from 2007 to 2013, just under US$6 mil-
lion in funding was awarded for Chagas disease vaccine research
and development (R&D, preventative and therapeutic), primarily
from major public sector funders including the Argentine Min-
istry of Science, Technology and Productive Innovation, German
Federal Ministry of Education and Research (BMBF), Institut Pas-
teur, and the US National Institutes of Health (NIH) [33]. Major
philanthropic funders such as the Bill & Melinda Gates Foundation
and the Wellcome Trust have not yet prioritized vaccine R&D for
the disease, though the Carlos Slim Foundation and the Japanese
Global Health Innovative Technology (GHIT) Fund have initiated
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ther private organizations including the Texas-based Kleberg
oundation, the Southwest Electronic Energy Medical Research
nstitute, and Texas Children’s Hospital. Because Chagas disease is
ndemic to both wealthy Latin American nations and the United
tates, and there is evidence of globalization of Chagas disease
o Europe, Australia, Japan, and elsewhere, this could potentially
ncentivise investment from the pharmaceutical industry upon pre-
linical and clinical proof-of-concept trials.
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